BioMed Research International

Cancer Immunotherapy and Identification of Prognostic and Predictive Biomarkers


Status
Published

1European Institute of Oncology, Milan, Italy

2Universita degli Studi di Napoli Federico II, Naples, Italy

3IRCCS Istituto Oncologico Veneto (IOV), Padova, Italy


Cancer Immunotherapy and Identification of Prognostic and Predictive Biomarkers

Description

Treatment strategies targeting the immune system provide the opportunity for antitumor activity across multiple cancer types regardless of mutational status or tumor histology. While many of the initial advances in immunotherapy have been in melanoma, the focus has now broadened to include many other solid as well as hematological cancers. Different immunotherapeutic approaches are being evaluated across tumor types and their various novel mechanisms of action and safety profiles offer the potential for a variety of combination regimens. Ongoing and planned investigation of these immunotherapies, alone and in combination, represents the start of a new chapter in our treatment of cancer and offers the hope of better outcomes for patients with a wide range of cancers. Recently, advances have been made in the use of immune-based approaches to treat other cancer types, such as non-small-cell lung cancer, breast cancer, ovarian cancer, gastrointestinal cancer, hepatocellular carcinoma, head and neck cancer, and lymphoma. We invite investigators to submit original research articles and reviews to this special issue.

Potential topics include but are not limited to the following:

  • Tumor and host factors controlling antitumor immunity and immunotherapy efficacy
  • Identification of prognostic and predictive biomarkers
  • Combinations of checkpoint inhibitors
  • Beyond PD-1/PD-L1 axis blockade: combinations or new molecules
  • Finding the best combination in immunotherapy: a paradigm shift in cancer therapy
  • Stimulation of anticancer immunity by new mechanisms and combinations
  • Antibody based immunotherapy
  • Adoptive T cell therapy
  • Different aspects of the interaction between cancer and the immune system
  • Immunooncology clinical studies across different tumor types

Articles

  • Special Issue
  • - Volume 2018
  • - Article ID 5184075
  • - Editorial

Cancer Immunotherapy and Identification of Prognostic and Predictive Biomarkers

Carmen Criscitiello | Michele Santangelo | Fotios Loupakis
  • Special Issue
  • - Volume 2017
  • - Article ID 8701386
  • - Research Article

Heterogeneous Periostin Expression in Different Histological Variants of Papillary Thyroid Carcinoma

Simona Eliza Giusca | Cornelia Amalinei | ... | Irina-Draga Căruntu
  • Special Issue
  • - Volume 2017
  • - Article ID 2605628
  • - Review Article

Current Tissue Molecular Markers in Colorectal Cancer: A Literature Review

Gaia Peluso | Paola Incollingo | ... | Nicola Carlomagno
  • Special Issue
  • - Volume 2017
  • - Article ID 7869802
  • - Review Article

Diagnostic, Predictive, Prognostic, and Therapeutic Molecular Biomarkers in Third Millennium: A Breakthrough in Gastric Cancer

Nicola Carlomagno | Paola Incollingo | ... | Michele Santangelo
  • Special Issue
  • - Volume 2017
  • - Article ID 1623679
  • - Review Article

Clinical Applications of Immunotherapy Combination Methods and New Opportunities for the Future

Ece Esin
  • Special Issue
  • - Volume 2017
  • - Article ID 5791262
  • - Review Article

Immunotherapeutic Strategies for Gastric Carcinoma: A Review of Preclinical and Clinical Recent Development

Mohamed Abozeid | Antonio Rosato | Roberta Sommaggio
  • Special Issue
  • - Volume 2017
  • - Article ID 4719194
  • - Review Article

Mismatch Repair Deficiency as a Predictive Biomarker for Immunotherapy Efficacy

Giulia Viale | Dario Trapani | Giuseppe Curigliano
  • Special Issue
  • - Volume 2017
  • - Article ID 4346576
  • - Review Article

Immunotherapy in Gastrointestinal Cancers

Letizia Procaccio | Marta Schirripa | ... | Sara Lonardi
  • Special Issue
  • - Volume 2017
  • - Article ID 5618174
  • - Review Article

Immunotherapy for Patients with Advanced Urothelial Cancer: Current Evidence and Future Perspectives

Clizia Zichi | Marcello Tucci | ... | Massimo Di Maio
BioMed Research International
 Journal metrics
Acceptance rate31%
Submission to final decision67 days
Acceptance to publication30 days
CiteScore3.600
Impact Factor2.276
 Submit

We are committed to sharing findings related to COVID-19 as quickly as possible. We will be providing unlimited waivers of publication charges for accepted research articles as well as case reports and case series related to COVID-19. Review articles are excluded from this waiver policy. Sign up here as a reviewer to help fast-track new submissions.